Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Review Article

晚期胆道癌的免疫检查点抑制剂

卷 22, 期 8, 2022

发表于: 31 March, 2022

页: [639 - 650] 页: 12

弟呕挨: 10.2174/1568009622666220215144235

价格: $65

摘要

BTC 是一种罕见的侵袭性癌症疾病，总体预后不佳，只有有限的治疗选择。 只有联合化疗方案才能实现疾病控制，这通常只是短暂的，因为肿瘤组织对化疗表现出高抗性。 近年来，免疫检查点抑制剂的出现显着提高了癌症患者的生存率，因此已被整合到几种实体瘤的治疗管理中，包括黑色素瘤、结直肠癌 (CRC)、肝细胞癌 (HCC)、三阴性 乳腺癌（TNBC）和非小细胞肺癌（NSCLC）。 对 BTC 肿瘤生物学的调查和初步研究结果表明，BTC 也可能适合免疫调节。 在这篇综述中，我们试图全面概述 ICPI 在 BTC 管理中的作用、潜力和临床意义。

关键词: 胆道癌、免疫治疗、免疫检查点抑制剂、PD-1/PD-L1、CTLA-4、癌。

« Previous Next »
[1]
Key statistics for bile duct cancer. 2018. Available from: https://www.cancer.org/cancer/bile-duct-cancer/about/key-statistics.html [cited 2020 December].
[2]
Jain, A.; Javle, M. Molecular profiling of biliary tract cancer: A target rich disease. J. Gastrointest. Oncol., 2016, 7(5), 797-803.
[http://dx.doi.org/10.21037/jgo.2016.09.01] [PMID: 27747093]
[3]
Zamani, Z.; Fatima, S. Biliary Tract Cancer; StatPearls: Treasure Island, FL, 2020.
[4]
Tariq, N.U.; McNamara, M.G.; Valle, J.W. Biliary tract cancers: Current knowledge, clinical candidates and future challenges. Cancer Manag. Res., 2019, 11, 2623-2642.
[http://dx.doi.org/10.2147/CMAR.S157092] [PMID: 31015767]
[5]
Edeline, J.; Benabdelghani, M.; Bertaut, A.; Watelet, J.; Hammel, P.; Joly, J.P.; Boudjema, K.; Fartoux, L.; Bouhier-Leporrier, K.; Jouve, J.L.; Faroux, R.; Guerin-Meyer, V.; Kurtz, J.E.; Assénat, E.; Seitz, J.F.; Baumgaertner, I.; Tougeron, D.; de la Fouchardière, C.; Lombard-Bohas, C.; Boucher, E.; Stanbury, T.; Louvet, C.; Malka, D.; Phelip, J.M. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A randomized phase III study. J. Clin. Oncol., 2019, 37(8), 658-667.
[http://dx.doi.org/10.1200/JCO.18.00050] [PMID: 30707660]
[6]
Valle, J.; Wasan, H.; Palmer, D.H.; Cunningham, D.; Anthoney, A.; Maraveyas, A.; Madhusudan, S.; Iveson, T.; Hughes, S.; Pereira, S.P.; Roughton, M.; Bridgewater, J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med., 2010, 362(14), 1273-1281.
[http://dx.doi.org/10.1056/NEJMoa0908721] [PMID: 20375404]
[7]
Lamarca, A. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J. Clin. Oncol., 2019, 37(Suppl. 15), 4003-4003.
[http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4003]
[8]
Oneda, E.; Abu Hilal, M.; Zaniboni, A. Biliary tract cancer: Current medical treatment strategies. Cancers (Basel), 2020, 12(5), E1237.
[http://dx.doi.org/10.3390/cancers12051237] [PMID: 32423017]
[9]
Survival rates for bile duct cancer. 2020. Available from: https://www.cancer.org/cancer/bile-duct-cancer/detection-diagnosis-staging/survival-by-stage.html [cited 2020 December].
[10]
Abou-Alfa, G.K.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A.S.; Borad, M.J.; Gallinson, D.; Murphy, A.G.; Oh, D.Y.; Dotan, E.; Catenacci, D.V.; Van Cutsem, E.; Ji, T.; Lihou, C.F.; Zhen, H.; Féliz, L.; Vogel, A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol., 2020, 21(5), 671-684.
[http://dx.doi.org/10.1016/S1470-2045(20)30109-1] [PMID: 32203698]
[11]
Herrscher, H.; Robert, C. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. Curr. Opin. Oncol., 2020, 32(2), 106-113.
[http://dx.doi.org/10.1097/CCO.0000000000000610] [PMID: 31876547]
[12]
Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducreux, M.; Kim, T.Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; Li, D.; Verret, W.; Xu, D.Z.; Hernandez, S.; Liu, J.; Huang, C.; Mulla, S.; Wang, Y.; Lim, H.Y.; Zhu, A.X.; Cheng, A.L. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med., 2020, 382(20), 1894-1905.
[http://dx.doi.org/10.1056/NEJMoa1915745] [PMID: 32402160]
[13]
Reddy, S.M.; Carroll, E.; Nanda, R. Atezolizumab for the treatment of breast cancer. Expert Rev. Anticancer Ther., 2020, 20(3), 151-158.
[http://dx.doi.org/10.1080/14737140.2020.1732211] [PMID: 32067545]
[14]
Lu, M.; Su, Y. Immunotherapy in non-small cell lung cancer: The past, the present, and the future. Thorac. Cancer, 2019, 10(4), 585-586.
[http://dx.doi.org/10.1111/1759-7714.13012] [PMID: 30821103]
[15]
Jakubowski, C.D.; Azad, N.S. Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). Chin. Clin. Oncol., 2020, 9(1), 2.
[http://dx.doi.org/10.21037/cco.2019.12.10] [PMID: 32008328]
[16]
Hui, E. Immune checkpoint inhibitors. J. Cell Biol., 2019, 218(3), 740-741.
[http://dx.doi.org/10.1083/jcb.201810035] [PMID: 30760493]
[17]
Buchbinder, E.I.; Desai, A. CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol., 2016, 39(1), 98-106.
[http://dx.doi.org/10.1097/COC.0000000000000239] [PMID: 26558876]
[18]
Seidel, J.A.; Otsuka, A.; Kabashima, K. Anti-PD-1 and Anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Front. Oncol., 2018, 8, 86.
[http://dx.doi.org/10.3389/fonc.2018.00086] [PMID: 29644214]
[19]
Heinzerling, L.; de Toni, E.N.; Schett, G.; Hundorfean, G.; Zimmer, L. Checkpoint inhibitors. Dtsch. Arztebl. Int., 2019, 116(8), 119-126.
[PMID: 30940340]
[20]
Piha-Paul, S.A.; Oh, D.Y.; Ueno, M.; Malka, D.; Chung, H.C.; Nagrial, A.; Kelley, R.K.; Ros, W.; Italiano, A.; Nakagawa, K.; Rugo, H.S.; de Braud, F.; Varga, A.I.; Hansen, A.; Wang, H.; Krishnan, S.; Norwood, K.G.; Doi, T. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int. J. Cancer, 2020, 147(8), 2190-2198.
[http://dx.doi.org/10.1002/ijc.33013] [PMID: 32359091]
[21]
Marabelle, A.; Le, D.T.; Ascierto, P.A.; Di Giacomo, A.M.; De Jesus-Acosta, A.; Delord, J.P.; Geva, R.; Gottfried, M.; Penel, N.; Hansen, A.R.; Piha-Paul, S.A.; Doi, T.; Gao, B.; Chung, H.C.; Lopez-Martin, J.; Bang, Y.J.; Frommer, R.S.; Shah, M.; Ghori, R.; Joe, A.K.; Pruitt, S.K.; Diaz, L.A., Jr Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II Keynote-158 study. J. Clin. Oncol., 2020, 38(1), 1-10.
[http://dx.doi.org/10.1200/JCO.19.02105] [PMID: 31682550]
[22]
Kang, J.; Jeong, J.H.; Hwang, H.S.; Lee, S.S.; Park, D.H.; Oh, D.W.; Song, T.J.; Kim, K.H.; Hwang, S.; Hwang, D.W.; Kim, S.C.; Park, J.H.; Hong, S.M.; Kim, K.P.; Ryoo, B.Y.; Yoo, C. Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: Tumor proportion score as a potential biomarker for response. Cancer Res. Treat., 2020, 52(2), 594-603.
[http://dx.doi.org/10.4143/crt.2019.493] [PMID: 32019287]
[23]
Ahn, S.; Lee, J.C.; Shin, D.W.; Kim, J.; Hwang, J.H. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Sci. Rep., 2020, 10(1), 12348.
[http://dx.doi.org/10.1038/s41598-020-69366-4] [PMID: 32704067]
[24]
Lee, S.H.; Lee, H.S.; Lee, S.H.; Woo, S.M.; Kim, D.U.; Bang, S. Efficacy and safety of pembrolizumab for gemcitabine/cisplatin-refractory biliary tract cancer: A multicenter retrospective study. J. Clin. Med., 2020, 9(6), E1769.
[http://dx.doi.org/10.3390/jcm9061769] [PMID: 32517311]
[25]
Arkenau, H.T.; Martin-Liberal, J.; Calvo, E.; Penel, N.; Krebs, M.G.; Herbst, R.S.; Walgren, R.A.; Widau, R.C.; Mi, G.; Jin, J.; Ferry, D.; Chau, I. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: Nonrandomized, open-label, phase I trial (JVDF). Oncologist, 2018, 23(12), 1407-e136.
[http://dx.doi.org/10.1634/theoncologist.2018-0044] [PMID: 29853658]
[26]
Lin, J.; Yang, X.; Long, J.; Zhao, S.; Mao, J.; Wang, D.; Bai, Y.; Bian, J.; Zhang, L.; Yang, X.; Wang, A.; Xie, F.; Shi, W.; Yang, H.; Pan, J.; Hu, K.; Guan, M.; Zhao, L.; Huo, L.; Mao, Y.; Sang, X.; Wang, K.; Zhao, H. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg. Nutr., 2020, 9(4), 414-424.
[http://dx.doi.org/10.21037/hbsn-20-338] [PMID: 32832493]
[27]
Finn, R.S. Abstract CT283: KEYNOTE-966: A randomized, double-blind, placebo-controlled, phase 3 study of pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract carcinoma. Cancer Res., 2020, 80(16)(Suppl.), CT283-CT283.
[28]
Ueno, M.; Ikeda, M.; Morizane, C.; Kobayashi, S.; Ohno, I.; Kondo, S.; Okano, N.; Kimura, K.; Asada, S.; Namba, Y.; Okusaka, T.; Furuse, J. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: A non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol. Hepatol., 2019, 4(8), 611-621.
[http://dx.doi.org/10.1016/S2468-1253(19)30086-X] [PMID: 31109808]
[29]
Kim, R.D.; Chung, V.; Alese, O.B.; El-Rayes, B.F.; Li, D.; Al-Toubah, T.E.; Schell, M.J.; Zhou, J.M.; Mahipal, A.; Kim, B.H.; Kim, D.W. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol., 2020, 6(6), 888-894.
[http://dx.doi.org/10.1001/jamaoncol.2020.0930] [PMID: 32352498]
[30]
Sahai, V. A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01). J. Clin. Oncol., 2020, 38(Suppl. 15), 4582-4582.
[http://dx.doi.org/10.1200/JCO.2020.38.15_suppl.4582]
[31]
Feng, K.; Liu, Y.; Zhao, Y.; Yang, Q.; Dong, L.; Liu, J.; Li, X.; Zhao, Z.; Mei, Q.; Han, W. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: Results from a phase II study. J. Immunother. Cancer, 2020, 8(1), e000367.
[http://dx.doi.org/10.1136/jitc-2019-000367] [PMID: 32487569]
[32]
Klein, O.; Kee, D.; Nagrial, A.; Markman, B.; Underhill, C.; Michael, M.; Jackett, L.; Lum, C.; Behren, A.; Palmer, J.; Tebbutt, N.C.; Carlino, M.S.; Cebon, J. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: Subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol., 2020, 6(9), 1405-1409.
[http://dx.doi.org/10.1001/jamaoncol.2020.2814] [PMID: 32729929]
[33]
Ioka, T. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J. Clin. Oncol., 2019, 37(Suppl. 4), 387-387.
[http://dx.doi.org/10.1200/JCO.2019.37.4_suppl.387]
[34]
Boilève, A.; Hilmi, M.; Gougis, P.; Cohen, R.; Rousseau, B.; Blanc, J.F.; Ben Abdelghani, M.; Castanié, H.; Dahan, L.; Tougeron, D.; Metges, J.P.; Tournigand, C.; Garcia-Larnicol, M.L.; Vernerey, D.; Turpin, A.; Neuzillet, C. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. Eur. J. Cancer, 2021, 143, 55-63.
[http://dx.doi.org/10.1016/j.ejca.2020.10.027] [PMID: 33279854]
[35]
Oh, D-Y. Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC). J. Clin. Oncol., 2020, 38(Suppl. 15), 4520-4520.
[http://dx.doi.org/10.1200/JCO.2020.38.15_suppl.4520]
[36]
Turkes, F.; Carmichael, J.; Cunningham, D.; Starling, N. Contemporary tailored oncology treatment of biliary tract cancers. Gastroenterol. Res. Pract., 2019, 2019, 7698786.
[http://dx.doi.org/10.1155/2019/7698786] [PMID: 31929787]
[37]
Rizzo, A.; Ricci, A.D.; Brandi, G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers (Basel), 2021, 13(3), 558.
[http://dx.doi.org/10.3390/cancers13030558] [PMID: 33535621]
[38]
Sha, D.; Jin, Z.; Budczies, J.; Kluck, K.; Stenzinger, A.; Sinicrope, F.A. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov., 2020, 10(12), 1808-1825.
[http://dx.doi.org/10.1158/2159-8290.CD-20-0522] [PMID: 33139244]
[39]
Apetoh, L.; Ladoire, S.; Coukos, G.; Ghiringhelli, F. Combining immunotherapy and anticancer agents: The right path to achieve cancer cure? Ann. Oncol., 2015, 26(9), 1813-1823.
[http://dx.doi.org/10.1093/annonc/mdv209] [PMID: 25922066]
[40]
Leonetti, A.; Wever, B.; Mazzaschi, G.; Assaraf, Y.G.; Rolfo, C.; Quaini, F.; Tiseo, M.; Giovannetti, E. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist. Updat., 2019, 46, 100644.
[http://dx.doi.org/10.1016/j.drup.2019.100644] [PMID: 31585395]
[41]
Robert, L.; Ribas, A.; Hu-Lieskovan, S. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin. Immunol., 2016, 28(1), 73-80.
[http://dx.doi.org/10.1016/j.smim.2016.01.001] [PMID: 26861544]
[42]
Khair, D.O.; Bax, H.J.; Mele, S.; Crescioli, S.; Pellizzari, G.; Khiabany, A.; Nakamura, M.; Harris, R.J.; French, E.; Hoffmann, R.M.; Williams, I.P.; Cheung, A.; Thair, B.; Beales, C.T.; Touizer, E.; Signell, A.W.; Tasnova, N.L.; Spicer, J.F.; Josephs, D.H.; Geh, J.L.; MacKenzie Ross, A.; Healy, C.; Papa, S.; Lacy, K.E.; Karagiannis, S.N. Combining immune checkpoint inhibitors: Established and emerging targets and strategies to improve outcomes in melanoma. Front. Immunol., 2019, 10, 453.
[http://dx.doi.org/10.3389/fimmu.2019.00453] [PMID: 30941125]
[43]
Valle, J.W.; Lamarca, A.; Goyal, L.; Barriuso, J.; Zhu, A.X. New horizons for precision medicine in biliary tract cancers. Cancer Discov., 2017, 7(9), 943-962.
[http://dx.doi.org/10.1158/2159-8290.CD-17-0245] [PMID: 28818953]

Rights & Permissions Print Cite
Article Metrics
18
1
© 2024 Bentham Science Publishers | Privacy Policy